124 related articles for article (PubMed ID: 19609487)
21. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
23. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis.
Aizu M; Mizushima I; Nakazaki S; Nakashima A; Kato T; Murayama T; Kato S; Katsuki Y; Ogane K; Fujii H; Yamada K; Nomura H; Yachie A; Yamagishi M; Kawano M
Mod Rheumatol; 2018 Jul; 28(4):592-598. PubMed ID: 28880691
[TBL] [Abstract][Full Text] [Related]
24. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
Levi M; Grange S; Frey N
J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
[TBL] [Abstract][Full Text] [Related]
25. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y
Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
Kaneshiro S; Ebina K; Hirao M; Tsuboi H; Nishikawa M; Nampei A; Nagayama Y; Takahi K; Noguchi T; Owaki H; Hashimoto J; Yoshikawa H
Mod Rheumatol; 2017 Jan; 27(1):42-49. PubMed ID: 27181115
[TBL] [Abstract][Full Text] [Related]
27. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
29. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis.
Hattori Y; Kida D; Kaneko A
Clin Rheumatol; 2019 Jan; 38(1):181-187. PubMed ID: 28940139
[TBL] [Abstract][Full Text] [Related]
30. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
Kaneko Y; Kondo H; Takeuchi T
J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
[TBL] [Abstract][Full Text] [Related]
31. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
[TBL] [Abstract][Full Text] [Related]
32. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
[TBL] [Abstract][Full Text] [Related]
33. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
34. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.
Yokoe I; Nishio S; Sato H; Kobayashi H
Mod Rheumatol; 2011 Dec; 21(6):710-4. PubMed ID: 21656090
[No Abstract] [Full Text] [Related]
35. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
Dörner T; Schulze-Koops H; Burmester GR; Iking-Konert C; Schmalzing M; Engel A; Kästner P; Kellner H; Kurthen R; Krüger K; Rubbert-Roth A; Schwenke H; Peters MA; Tony HP
Clin Exp Rheumatol; 2019; 37(6):937-945. PubMed ID: 31025930
[TBL] [Abstract][Full Text] [Related]
36. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
[TBL] [Abstract][Full Text] [Related]
37. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
[TBL] [Abstract][Full Text] [Related]
38. The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.
Hirabayashi Y; Ishii T;
Clin Rheumatol; 2013 Jan; 32(1):123-7. PubMed ID: 23090655
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
40. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
Urata Y; Uesato R; Tanaka D; Nakamura Y; Motomura S
Ann Rheum Dis; 2012 Apr; 71(4):534-40. PubMed ID: 22021897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
